12:00 AM
 | 
Sep 24, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Pomalidomide regulatory update

FDA's Oncologic Drugs Advisory Committee (ODAC) will meet on Nov. 8 to discuss an NDA from Celgene for pomalidomide in combination with...

Read the full 86 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >